BIOVICA INTERNATIONAL AB SER. BBB

BIOVICA INTERNATIONAL AB SER. B

1.940SEKD
+0.158+8.87%
At close at Jan 10, 16:23 UTC
SEK
No trades
See on Supercharts

BIOVIC_B fundamentals

Key facts

Market capitalization‪175.27 M‬SEK
Basic EPS (TTM)−1.41SEK
Founded2008
CEOAnders Rylander
About

Biovica International AB is engages in the development and commercialization of novel blood-based biomarker assays to improve the monitoring of modern cancer therapies. It offers DiviTum assay, which is intended to monitor and predict treatment response in cancer patients. The company was founded in 2009 and is headquartered in Uppsala, Sweden.

Ownership
‪‪83.84 M‬‬
Free Float shares
‪‪80.47 M‬‬ (95.98%)
Closely held shares
‪‪3.37 M‬‬ (4.02%)
Free Float shares
‪‪80.47 M‬‬ (95.98%)
Closely held shares
‪‪3.37 M‬‬ (4.02%)
Capital structure
Market cap
‪‪175.27 M‬‬
Debt
‪‪6.86 M‬‬
Cash & equivalents
‪‪61.88 M‬‬
Enterprise value
‪‪120.24 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪175.27 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
23.12x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
23.12x
Valuation ratios
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
‪0.00‬
‪9.00‬
‪18.00‬
‪27.00‬
‪36.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−2,700.00%‬
‪−2,250.00%‬
‪−1,800.00%‬
‪−1,350.00%‬
‪−900.00%‬
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
‪‪−45.00 M‬‬
‪‪−30.00 M‬‬
‪‪−15.00 M‬‬
‪0.00‬
‪‪15.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−24.00 M‬‬
‪‪−16.00 M‬‬
‪‪−8.00 M‬‬
‪0.00‬
‪‪8.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−24.00 M‬‬
‪‪−16.00 M‬‬
‪‪−8.00 M‬‬
‪0.00‬
‪‪8.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Research Test
Research Kit
In Vitro Diagnostics
By country
Period: 2023
United States
European Union excluding Sweden
Asia
Sweden

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪2.50 M‬‬
‪‪5.00 M‬‬
‪‪7.50 M‬‬
‪‪10.00 M‬‬
Actual
Estimate
Earnings
Next:Mar 13
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪−0.44‬
‪−0.33‬
‪−0.22‬
‪−0.11‬
‪0.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

BIOVIC_B does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
‪‪−40.00 M‬‬
‪0.00‬
‪‪40.00 M‬‬
‪‪80.00 M‬‬
‪‪120.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪20.00 M‬‬
‪‪40.00 M‬‬
‪‪60.00 M‬‬
‪‪80.00 M‬‬
Assets
Liabilities